

**Breast & Cervical Cancer Control Program (BCCCP)
and WISEWOMAN Program
Tobacco Use Screening Policy**

Title: BCCCP/WISEWOMAN Tobacco Use Screening Policy	Category/Number: BCCCP/WISEWOMAN
Approved By: <u>Kimberly McDonald</u> BCCCP Medical Advisor <u>Heather Dolinger</u> BCCCP Program Manager	Section: BCCCP Training Manual - Appendices Program: BCCCP/WISEWOMAN
Effective Date: <u>07/01/2024</u> Current Revision Effective Date: <u>02/11/25</u> Revision History Date/s: <u>07/01/24; 02/11/25</u>	Review Date/s: <u>7/18/24; 02/11/25</u> <hr/> <hr/>

Purpose: Tobacco use is associated with many cancers and chronic diseases that impact the health of our nation. The CDC mandates that BCCCP/WISEWOMAN providers assess the use of tobacco for every person screened by local BCCCP/WISEWOMAN programs and refer those who use tobacco to a tobacco cessation program.

Policy: Local BCCCP/WISEWOMAN providers shall assess tobacco use for each person enrolled and screened by their program. People who use tobacco shall be referred to QuitlineNC (or a comparable tobacco cessation program). Assessment and referral documentation or participant declination will become part of the patient’s medical record.

Definitions: Tobacco users are individuals who self-report having smoked tobacco (e.g., cigarettes, cigars), used smokeless tobacco, and/or vaped using an electronic nicotine delivery system within the past 30 days.¹

Tobacco-derived product: (a) Tobacco product - Any noncombustible product derived from tobacco that contains nicotine and is intended for human consumption, whether chewed, absorbed, dissolved, ingested, or by any other means. (b) Vapor product - Any noncombustible product that employs a mechanical heating element, battery, or electronic circuit regardless of shape or size and that can be used to heat a liquid nicotine solution contained in a vapor cartridge. The term includes an electronic cigarette, electronic cigar, electronic cigarillo, and electronic pipe.

¹ Public Health Law Center

The terms, ‘tobacco product’ and ‘vapor product’ do not include any product regulated by the United States Food and Drug Administration under Chapter V of the federal Food, Drug, and Cosmetic Act (e.g., an FDA-approved tobacco treatment medication such as nicotine replacement therapy).²

Responsibilities: Local BCCCP/WISEWOMAN providers are required to assess the use of tobacco for every patient enrolled and screened by their BCCCP and/or WISEWOMAN programs.

Procedure: Local BCCCP/WISEWOMAN providers shall assess each person enrolled and screened by their program for tobacco use. People who use tobacco shall be referred to [QuitlineNC](#) or a comparable tobacco cessation program. Assure that assessment and referral documentation and/or documentation of participant declination becomes part of the patient’s medical record.

Legal Authority:

National Breast and Cervical Cancer Early Detection Program (NBCCEDP)³
North Carolina Department of Health and Human Services (DHHS)

References:

Centers for Disease Control and Prevention, National Breast and Cervical Cancer Early Detection Program, DP22-2202 Program Manual: Part I Program Implementation. Version 1.1/July 2022

[NC General Statute § 14-313 \(a\)](#)

[North Carolina Tobacco Prevention and Control Branch](#)

[Public Health Law Center](#)

² North Carolina General Statute § 14-313 (a)

³ National Breast & Cervical Cancer Early Detection Program